100 Recruiting Studies Using Nivolumab
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Nivolumab
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Anal Basaloid Carcinoma
View Study & Checklist ➔A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
📍 University of Rochester — Rochester, New York
Pancreatic Ductal Adenocarcinoma
View Study & Checklist ➔CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer
📍 City of Hope Medical Center — Duarte, California
Advanced Clear Cell Renal Cell Carcinoma
View Study & Checklist ➔Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity
📍 Dana Farber Cancer Institute — Boston, Massachusetts
Head and Neck Cancer
View Study & Checklist ➔Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
📍 Duke Cancer Institute — Durham, North Carolina
Melanoma Stage III
View Study & Checklist ➔Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Stage IB Lung Non-Small Cell Carcinoma AJCC v7
View Study & Checklist ➔Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer
📍 Providence Portland Medical Center — Portland, Oregon
BRAF NP_004324.2:p.V600M
View Study & Checklist ➔A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
📍 Arizona Oncology Associates, PC - HAL — Phoenix, Arizona
Epithelial Ovarian Cancer
View Study & Checklist ➔Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
📍 State University of Iowa — Iowa City, Iowa
Advanced Solid Tumor
View Study & Checklist ➔NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Breast Cancer
View Study & Checklist ➔Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma
📍 Mayo Clinic- Florida — Jacksonville, Florida
Mucosal Melanoma
View Study & Checklist ➔Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer
📍 M D Anderson Cancer Center — Houston, Texas
Metastatic Malignant Neoplasm in the Brain
View Study & Checklist ➔Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation
📍 City of Hope Medical Center — Duarte, California
Recurrent Transformed Chronic Lymphocytic Leukemia
View Study & Checklist ➔Nivolumab+Ipilimumab+RT in MSS mCRC
📍 Massachusetts General Hospital Cancer Center — Boston, Massachusetts
Metastatic Microsatellite Stable Colorectal Cancer
View Study & Checklist ➔NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
📍 Dana-Farber Cancer Institute — Boston, Massachusetts
Melanoma
View Study & Checklist ➔NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
📍 University of California San Francisco — San Francisco, California
Radiotherapy
View Study & Checklist ➔Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma
📍 Karmanos Cancer Institute — Detroit, Michigan
Hodgkin Lymphoma
View Study & Checklist ➔Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
📍 M D Anderson Cancer Center — Houston, Texas
Clinical Stage III Cutaneous Melanoma AJCC v8
View Study & Checklist ➔Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial
📍 Thomas Hospital — Fairhope, Alabama
Advanced Melanoma
View Study & Checklist ➔A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
📍 Local Institution - 0022 — Tucson, Arizona
Urinary Bladder Neoplasms
View Study & Checklist ➔Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
📍 Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland
Hepatocellular Carcinoma
View Study & Checklist ➔REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
📍 Johns Hopkins University — Baltimore, Maryland
Gastroesophageal Cancer
View Study & Checklist ➔A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Leiomyosarcoma
View Study & Checklist ➔A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
📍 Scottsdale Healthcare /ID# 123761 — Scottsdale, Arizona
Advanced Solid Tumors Cancer
View Study & Checklist ➔Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers
📍 University of Colorado Anschutz Medical Campus — Aurora, Colorado
Bronchial Dysplasia
View Study & Checklist ➔Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients
📍 Moffitt Cancer Center — Tampa, Florida
Metastatic Urothelial Carcinoma
View Study & Checklist ➔A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
📍 GSK Investigational Site — Goodyear, Arizona
Neoplasms
View Study & Checklist ➔A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
📍 HonorHealth Research Institute — Scottsdale, Arizona
Solid Tumor
View Study & Checklist ➔Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer
📍 Georgetown Lombardi Comprehensive Cancer Center — Washington D.C., District of Columbia
Pancreatic Ductal Adenocarcinoma
View Study & Checklist ➔Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
📍 Zuckerberg San Francisco General Hospital — San Francisco, California
AIDS-Related Anal Carcinoma
View Study & Checklist ➔Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
📍 Los Angeles General Medical Center — Los Angeles, California
Anaplastic Large Cell Lymphoma, ALK-Negative
View Study & Checklist ➔Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Locally Advanced Extraskeletal Myxoid Chondrosarcoma
View Study & Checklist ➔A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
📍 The Angeles Clinic — Los Angeles, California
Melanoma
View Study & Checklist ➔Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer
📍 M D Anderson Cancer Center — Houston, Texas
Clinical Stage 0 Gastric Cancer AJCC v8
View Study & Checklist ➔NeoVax With Nivolumab in Patients With Ovarian Cancer
📍 Dana Farber Cancer Institute — Boston, Massachusetts
Ovarian Cancer
View Study & Checklist ➔Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers
📍 UCSF Benioff Children's Hospital — San Francisco, California
Malignant Rhabdoid Tumor
View Study & Checklist ➔Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Acute Myeloid Leukemia
View Study & Checklist ➔A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
📍 UT Southwestern Medical Center — Dallas, Texas
Metastatic Renal Cell Carcinoma
View Study & Checklist ➔MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
📍 Research Site — Santa Rosa, California
Unresectable Pleural Mesothelioma
View Study & Checklist ➔Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Locally Advanced Bladder Urothelial Carcinoma
View Study & Checklist ➔Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
📍 Children's Hospital of Alabama — Birmingham, Alabama
Recurrent Classic Hodgkin Lymphoma
View Study & Checklist ➔A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
📍 Local Institution - 0059 — Los Angeles, California
Metastatic Colorectal Cancer
View Study & Checklist ➔Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer
📍 Veterans Administration Medical Center - Birmingham — Birmingham, Alabama
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma
View Study & Checklist ➔Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
📍 Exelixis Clinical Site #116 — La Jolla, California
Renal Cell Carcinoma
View Study & Checklist ➔Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
📍 University of Alabama at Birmingham, Children's of Alabama — Birmingham, Alabama
Glioblastoma
View Study & Checklist ➔Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
📍 Northwestern University — Chicago, Illinois
Glioblastoma
View Study & Checklist ➔Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
📍 Johns Hopkins University — Baltimore, Maryland
Gastric Cancer
View Study & Checklist ➔ARID1A and/or KDM6A Mutation and CXCL13 Expression
📍 M D Anderson Cancer Center — Houston, Texas
Locally Advanced Bladder Urothelial Carcinoma
View Study & Checklist ➔A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation
📍 Local Institution - 0081 — Anniston, Alabama
Hepatocellular Carcinoma
View Study & Checklist ➔Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
📍 H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
Merkel Cell Carcinoma
View Study & Checklist ➔Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Pancreatic Adenocarcinoma
View Study & Checklist ➔Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
📍 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
Pancreatic Cancer
View Study & Checklist ➔Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
📍 M D Anderson Cancer Center — Houston, Texas
Acral Lentiginous Melanoma
View Study & Checklist ➔Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
📍 Mayo Clinic in Rochester — Rochester, Minnesota
Clinical Stage IV Gastric Cancer AJCC v8
View Study & Checklist ➔A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
📍 Abramson Cancer Center at University of Pennsylvania — Philadelphia, Pennsylvania
Melanoma
View Study & Checklist ➔A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
📍 Local Institution - 0104 — Tampa, Florida
Carcinoma, Non-Small-Cell Lung
View Study & Checklist ➔Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
📍 CTCA at Western Regional Medical Center — Goodyear, Arizona
Metastatic Colon Adenocarcinoma
View Study & Checklist ➔Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma
📍 Johns Hopkins — Baltimore, Maryland
Renal Cell Carcinoma
View Study & Checklist ➔Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
📍 University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
Prostate Cancer
View Study & Checklist ➔Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
📍 H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
Non Small Cell Lung Cancer
View Study & Checklist ➔Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Ann Arbor Stage I Hodgkin Lymphoma
View Study & Checklist ➔Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Resectable Lung Non-Small Cell Carcinoma
View Study & Checklist ➔Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
📍 Levine Cancer Institute — Charlotte, North Carolina
Multiple Myeloma
View Study & Checklist ➔A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
📍 Massachusetts General Hospital — Boston, Massachusetts
Peritoneal Cancer
View Study & Checklist ➔Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Recurrent Squamous Cell Lung Carcinoma
View Study & Checklist ➔Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma
📍 Utah University School of Medicine/Huntsman Cancer Institute — Salt Lake City, Utah
Hodgkin Lymphoma
View Study & Checklist ➔A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Stage III Cutaneous Melanoma AJCC v7
View Study & Checklist ➔SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma
📍 Children's Hospital of Los Angeles — Los Angeles, California
Osteosarcoma
View Study & Checklist ➔Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Metastatic Renal Cell Carcinoma
View Study & Checklist ➔A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
📍 California Pacific Medical Center Research Institute — San Francisco, California
Melanoma
View Study & Checklist ➔Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8
View Study & Checklist ➔pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer
📍 University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
Prostate Cancer
View Study & Checklist ➔A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
Astrocytoma, IDH-Mutant, Grade 4
View Study & Checklist ➔Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
📍 Emory University — Atlanta, Georgia
Grade 3a Follicular Lymphoma
View Study & Checklist ➔Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck
📍 Ohio State University — Columbus, Ohio
Lip
View Study & Checklist ➔Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Advanced Lymphoma
View Study & Checklist ➔Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Aggressive Non-Hodgkin Lymphoma
View Study & Checklist ➔A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain
📍 Memorial Sloan Kettering Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey
Metastatic Renal Cell Carcinoma
View Study & Checklist ➔Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Advanced Endometrial Carcinoma
View Study & Checklist ➔A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
📍 Local Institution - 0125 — Phoenix, Arizona
Melanoma
View Study & Checklist ➔Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
📍 M D Anderson Cancer Center — Houston, Texas
BRAF NP_004324.2:p.V600E
View Study & Checklist ➔A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
📍 Children's Hospital of Alabama — Birmingham, Alabama
Metastatic Renal Cell Carcinoma
View Study & Checklist ➔Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Bladder Small Cell Neuroendocrine Carcinoma
View Study & Checklist ➔Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer
📍 Thomas Hospital — Fairhope, Alabama
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
View Study & Checklist ➔Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer
📍 Moffitt Cancer Center — Tampa, Florida
Bladder Cancer
View Study & Checklist ➔A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
📍 Local Institution - 0021 — Los Angeles, California
Advanced Solid Tumors
View Study & Checklist ➔Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
📍 Los Angeles General Medical Center — Los Angeles, California
Advanced Malignant Skin Neoplasm
View Study & Checklist ➔Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
📍 Los Angeles General Medical Center — Los Angeles, California
Anal Canal Squamous Cell Carcinoma
View Study & Checklist ➔Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
📍 Exelixis Clinical Site #1 — Duarte, California
Non-Clear Cell Renal Cell Carcinoma
View Study & Checklist ➔Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer
📍 Mobile Infirmary Medical Center — Mobile, Alabama
Locally Advanced Rectal Adenocarcinoma
View Study & Checklist ➔Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
📍 Cedars Sinai Medical Center — Los Angeles, California
Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy
View Study & Checklist ➔Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours
📍 University of Iowa — Iowa City, Iowa
Advanced Solid Tumor
View Study & Checklist ➔Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
📍 University of California, San Diego — La Jolla, California
Hormone Sensitive Prostate Cancer
View Study & Checklist ➔De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Basaloid Squamous Cell Carcinoma
View Study & Checklist ➔Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients
📍 Memorial Sloan Kettering Cancer Center — New York, New York
Breast Neoplasm Female
View Study & Checklist ➔Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
📍 H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida
Melanoma (Skin)
View Study & Checklist ➔Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
📍 Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
Cutaneous Melanoma, Stage III
View Study & Checklist ➔Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma
📍 City of Hope Medical Center — Duarte, California
Classic Hodgkin Lymphoma
View Study & Checklist ➔Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla
📍 MD Anderson Cancer Center — Houston, Texas
Carcinomas
View Study & Checklist ➔Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.
📍 Duke Cancer Institute — Durham, North Carolina
Renal Cell Carcinoma
View Study & Checklist ➔